Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

In the last few years, Chinese AI startup MiniMax has become one of the most exciting in the crowded global AI marketplace, ...

DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- When Jensen Huang talks about the future of technology, markets tend to listen. After leading NVIDIA (NASDAQ:NVDA) to become one of the most valuable ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc.

Costumed beasts and creepy crawlies aren’t limited to Halloween. This week a wild and woolly band of bloodthirsty space ...